Literature DB >> 21181123

Selective blockade of the orexin-2 receptor attenuates ethanol self-administration, place preference, and reinstatement.

James R Shoblock1, Natalie Welty, Leah Aluisio, Ian Fraser, S Timothy Motley, Kirsten Morton, James Palmer, Pascal Bonaventure, Nicholas I Carruthers, Timothy W Lovenberg, Jamin Boggs, Ruggero Galici.   

Abstract

RATIONALE: Orexin-1 receptor antagonists have been shown to block the reinforcing effects of drugs of abuse and food. However, whether blockade of orexin-2 receptor has similar effects has not been determined. We have recently described the in vitro and in vivo effects of JNJ-10397049, a selective and brain penetrant orexin-2 receptor antagonist.
OBJECTIVE: The goal of these studies was to evaluate whether systemic administration of JNJ-10397049 blocks the rewarding effects of ethanol and reverses ethanol withdrawal in rodents. As a comparison, SB-408124, a selective orexin-1 receptor antagonist, was also evaluated.
METHODS: Rats were trained to orally self-administer ethanol (8% v/v) or saccharin (0.1% v/v) under a fixed-ratio 3 schedule of reinforcement. A separate group of rats received a liquid diet of ethanol (8% v/v) and withdrawal signs were evaluated 4 h after ethanol discontinuation. In addition, ethanol-induced increases in extracellular dopamine levels in the nucleus accumbens were tested. In separate experiments, the acquisition, expression, and reinstatement of conditioned place preference (CPP) were evaluated in mice.
RESULTS: Our results indicate that JNJ-10397049 (1, 3, and 10 mg/kg, sc) dose-dependently reduced ethanol self-administration without changing saccharin self-administration, dopamine levels, or withdrawal signs in rats. Treatment with JNJ-10397049 (10 mg/kg, sc) attenuated the acquisition, expression, and reinstatement of ethanol CPP and ethanol-induced hyperactivity in mice. Surprisingly, SB-408124 (3, 10 and 30 mg/kg, sc) did not have any effect in these procedures.
CONCLUSIONS: Collectively, these results indicate, for the first time, that blockade of orexin-2 receptors is effective in reducing the reinforcing effects of ethanol.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21181123     DOI: 10.1007/s00213-010-2127-x

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  52 in total

1.  Modulation of ethanol withdrawal-induced anxiety-like behavior during later withdrawals by treatment of early withdrawals with benzodiazepine/gamma-aminobutyric acid ligands.

Authors:  Darin J Knapp; David H Overstreet; George R Breese
Journal:  Alcohol Clin Exp Res       Date:  2005-04       Impact factor: 3.455

2.  Direct involvement of orexinergic systems in the activation of the mesolimbic dopamine pathway and related behaviors induced by morphine.

Authors:  Minoru Narita; Yasuyuki Nagumo; Seiko Hashimoto; Michiko Narita; Junaidi Khotib; Mayumi Miyatake; Takeshi Sakurai; Masashi Yanagisawa; Tomoya Nakamachi; Seiji Shioda; Tsutomu Suzuki
Journal:  J Neurosci       Date:  2006-01-11       Impact factor: 6.167

3.  Effects of prolonged-release melatonin, zolpidem, and their combination on psychomotor functions, memory recall, and driving skills in healthy middle aged and elderly volunteers.

Authors:  S Otmani; A Demazières; C Staner; N Jacob; T Nir; N Zisapel; L Staner
Journal:  Hum Psychopharmacol       Date:  2008-12       Impact factor: 1.672

Review 4.  Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review.

Authors:  Carmen Bouza; Magro Angeles; Angeles Magro; Ana Muñoz; José María Amate
Journal:  Addiction       Date:  2004-07       Impact factor: 6.526

5.  Orexin-1 receptor antagonism decreases ethanol consumption and preference selectively in high-ethanol--preferring Sprague--Dawley rats.

Authors:  David E Moorman; Gary Aston-Jones
Journal:  Alcohol       Date:  2009-08       Impact factor: 2.405

6.  Distinct subsets of nucleus accumbens neurons encode operant responding for ethanol versus water.

Authors:  Donita L Robinson; Regina M Carelli
Journal:  Eur J Neurosci       Date:  2008-11       Impact factor: 3.386

7.  Orexin A in the VTA is critical for the induction of synaptic plasticity and behavioral sensitization to cocaine.

Authors:  Stephanie L Borgland; Sharif A Taha; Federica Sarti; Howard L Fields; Antonello Bonci
Journal:  Neuron       Date:  2006-02-16       Impact factor: 17.173

Review 8.  Role of lateral hypothalamic orexin neurons in reward processing and addiction.

Authors:  Gary Aston-Jones; Rachel J Smith; David E Moorman; Kimberlei A Richardson
Journal:  Neuropharmacology       Date:  2008-07-04       Impact factor: 5.250

9.  Biochemical and electrophysiological characterization of almorexant, a dual orexin 1 receptor (OX1)/orexin 2 receptor (OX2) antagonist: comparison with selective OX1 and OX2 antagonists.

Authors:  Pari Malherbe; Edilio Borroni; Emmanuel Pinard; Joseph G Wettstein; Frédéric Knoflach
Journal:  Mol Pharmacol       Date:  2009-06-19       Impact factor: 4.436

10.  Effects of various serotonergic agents on alcohol intake and alcohol preference in Wistar rats selected at two different levels of alcohol preference.

Authors:  T F Meert
Journal:  Alcohol Alcohol       Date:  1993-03       Impact factor: 2.826

View more
  63 in total

1.  Differential orexin/hypocretin expression in addiction-prone and -resistant rats selectively bred for high (HiS) and low (LoS) saccharin intake.

Authors:  Nathan A Holtz; Natalie E Zlebnik; Marilyn E Carroll
Journal:  Neurosci Lett       Date:  2012-06-02       Impact factor: 3.046

2.  Relative potency of varenicline or fluvoxamine to reduce responding for ethanol versus food depends on the presence or absence of concurrently earned food.

Authors:  Brett C Ginsburg; Richard J Lamb
Journal:  Alcohol Clin Exp Res       Date:  2014-03       Impact factor: 3.455

3.  Orexin-1 receptor antagonism does not reduce the rewarding potency of cocaine in Swiss-Webster mice.

Authors:  Thorfinn T Riday; Eric W Fish; J Elliott Robinson; Thomas M Jarrett; Megan M McGuigan; C J Malanga
Journal:  Brain Res       Date:  2011-11-07       Impact factor: 3.252

4.  Orexin/hypocretin-1 receptor antagonism reduces ethanol self-administration and reinstatement selectively in highly-motivated rats.

Authors:  David E Moorman; Morgan H James; Elisabeth A Kilroy; Gary Aston-Jones
Journal:  Brain Res       Date:  2016-10-19       Impact factor: 3.252

5.  The orexin-1 receptor antagonist SB-334867 decreases sympathetic responses to a moderate dose of methamphetamine and stress.

Authors:  Daniel E Rusyniak; Dmitry V Zaretsky; Maria V Zaretskaia; Pamela J Durant; Joseph A DiMicco
Journal:  Physiol Behav       Date:  2012-02-14

Review 6.  Multiple roles for orexin/hypocretin in addiction.

Authors:  Stephen V Mahler; Rachel J Smith; David E Moorman; Gregory C Sartor; Gary Aston-Jones
Journal:  Prog Brain Res       Date:  2012       Impact factor: 2.453

Review 7.  Neurobiology of consummatory behavior: mechanisms underlying overeating and drug use.

Authors:  Jessica R Barson; Irene Morganstern; Sarah F Leibowitz
Journal:  ILAR J       Date:  2012

Review 8.  Systems level neuroplasticity in drug addiction.

Authors:  Matthew W Feltenstein; Ronald E See
Journal:  Cold Spring Harb Perspect Med       Date:  2013-05-01       Impact factor: 6.915

Review 9.  Therapeutics development for addiction: Orexin-1 receptor antagonists.

Authors:  David A Perrey; Yanan Zhang
Journal:  Brain Res       Date:  2018-08-24       Impact factor: 3.252

10.  Roux en Y gastric bypass increases ethanol intake in the rat.

Authors:  Jon F Davis; Andrea L Tracy; Jennifer D Schurdak; Irwin J Magrisso; Bernadette E Grayson; Randy J Seeley; Stephen C Benoit
Journal:  Obes Surg       Date:  2013-07       Impact factor: 4.129

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.